Topic

All

26
Dec
2018

Messenger RNA Therapies That You May Not Have Heard Of: Ron Renaud on The Long Run

Today’s guest on The Long Run is Ron Renaud. Ron is the CEO of Lexington, Mass.-based Translate Bio. The company is working on messenger RNA therapies. You may have heard about this technology. mRNA molecules provide genetic instructions for making proteins. The idea is to restore functional proteins that, for one reason or another, have gone awry in a disease...
Read More
12
Dec
2018

First Everest, Now Kilimanjaro: Climb With Me and a Great Biotech Team to Fight Cancer

Summiting the highest peak in the world and raising $340,000 for cancer research at Fred Hutch was the start. It was the start of something bigger. Today, I’m overjoyed to say that an outstanding team of biotech executives and investors will join me on the Kilimanjaro Climb to Fight Cancer. This will be a 7-day expedition to the summit of...
Read More
15
Nov
2018

China Biotech: Six Things to Watch in 2019

More than $1.5 billion in cash flooded into four IPOs offerings for China-based drug developers this year. These were just the first. The China biotech IPO opening was — and will continue to be — a big ongoing story. In April, the Hong Kong Stock Exchange relaxed rules allowing public stock investment in pre-revenue (development-stage) biotech companies. In July, the...
Read More
14
Nov
2018

From Nova Scotia to the Forefront of Bio & Tech Investing: Julie Sunderland of Biomatics on The Long Run

Julie Sunderland is the guest on the latest episode of The Long Run podcast. She is a managing director at Biomatics Capital, a Seattle-based venture firm that invests in what it calls “data-enabled healthcare.” Before diving into that, as always, I want listeners to get to know the person making things happen, and how she got here. Sunderland her fellow...
Read More
1
Nov
2018

Exploring Synthetic Lethal Cancer Drug Discovery: Barbara Weber on The Long Run

Today’s guest on The Long Run podcast is Barbara Weber. She is the CEO of Cambridge, Mass.-based Tango Therapeutics. Ever hear the saying ‘it takes two to tango?’ That’s where this startup draws its inspiration. It’s seeking to discover and develop synthetic lethal cancer drugs. These are intended to target two molecular vulnerabilities of a cancer cell, not just one,...
Read More
30
Oct
2018

Nine VCs Who Matter, But You Never Read About

Venture capitalists see a steady stream of people asking for money and currying favor. This can inflate the ego to unhealthy proportions. The best VCs, however, don’t let all that get to their head. They also don’t just write checks. They help entrepreneurs. Quite a few of the best VCs in biotech tend to work behind the scenes. You don’t...
Read More